Bispecific antibody targets and services

Booth No: M1033

Characteristic

Bispecific antibodies (bsAbs) harness the specificities of two antibodies and combine them to simultaneously recognize different antigens or epitopes. This 'two-target' functionality has meant that interest in their use for therapeutic applications has increased considerably. With the development and maturity of bsAb technology platform, the combination selection of targets is becoming the key point of competition. Among the bsAb programs under development currently, the combination of CD3 and tumor surface targets are the most popular targets pairs. And the new targets of Immune cell will also provide more choice in targets combination in the future.
Feature products
CD3 Proteins
(1) MALS verified heterodimer
(2) High bioactivity and batch-to-batch consistency
(3) Bioactivity verified by clinical bispecific antibody
(4) Various tags and species
PD-1/PD-L1 Proteins
(1) High purity and homogeneity
(2) High bioactivity verified
(3) Various tags and species
CD47 Proteins
(1) High purity and homogeneity
(2) High bioactivity verified
(3) Suitable for immunization and inhibitor
Full Length CD20 Proteins
(1) Authentic conformation
(2) Super bioactivity verified
(3) Exclusive Nanodisc technology